Related Experiment Videos
Quality assurance and dosimetric evaluation for an endocavitary unit
1Mallinckrodt Institute of Radiology, Radiation Oncology Center, Washington University School of Medicine, St. Louis, MO 63110.
Summary
Endocavitary contact therapy effectively treats rectal cancer using high-dose-rate X-rays. A robust quality assurance program ensures accurate dosimetry and radiation safety in the operating room.
Area of Science:
- Radiation Oncology
- Medical Physics
Background:
- Endocavitary contact therapy is an effective treatment for selected rectal carcinomas.
- High dose rates and rapid dose fall-off present dosimetric and quality assurance challenges.
- Operating room environments pose radiation safety concerns due to variable conditions.
Purpose of the Study:
- To establish and assess a comprehensive quality assurance (QA) program for endocavitary contact therapy.
- To ensure accurate dosimetry and radiation safety during treatment.
- To validate the reliability of the treatment delivery system.
Main Methods:
- Utilized a 50 kVp X-ray unit with specific source-to-surface distance (SSD) and applicators.
- Implemented daily, monthly, and annual QA reviews.
- Employed parallel-plate ionization chambers, silver bromide film, electron diode systems, and ion chamber survey meters for dosimetry and radiation measurements.
- Conducted output checks, relative depth dose measurements, beam profile evaluations, and scatter/leakage assessments.
Main Results:
- Daily output checks confirmed stability across different operating rooms.
- Monthly ion chamber checks validated output trends.
- Percent depth dose measurements in liquid water and polystyrene agreed with published data.
- Radiation surveys indicated acceptable exposure levels.
Conclusions:
- A comprehensive QA program, including day-of-treatment output checks, enhances confidence in dose delivery.
- The established QA protocols effectively address dosimetric and radiation safety challenges.
- Endocavitary contact therapy, supported by rigorous QA, remains a viable treatment option for rectal cancer.